ERBB2 and inflammatory breast carcinoma: Interestingly, an E2F4 activation expression signature associated with sensitivity to palbociclib and resistance to aromatase inhibitors (Guerrero‐Zotano et al., 2018) was higher in IBC than in non‐IBC samples, notably in HR+/HER2− patients.